{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:09:48Z","timestamp":1790712588955,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T00:00:00Z","timestamp":1563580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Plazomicin (ACHN-490) is a novel parenteral aminoglycoside developed to target multidrug-resistant Enterobacteriaceae. It has recently been approved by the Food and Drug Administration for the management of complicated urinary tract infections and pyelonephritis caused by susceptible organisms. When compared with meropenem, plazomicin was not inferior. The adverse-event profile for plazomicin was comparable to meropenem except for an increased additional rise in serum creatinine in the plazomicin arm compared with the meropenem arm. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.<\/jats:p>","DOI":"10.1093\/cid\/ciz640","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T15:19:18Z","timestamp":1563463158000},"page":"704-709","source":"Crossref","is-referenced-by-count":52,"title":["Plazomicin: A New Aminoglycoside"],"prefix":"10.1093","volume":"70","author":[{"given":"Louis D","family":"Saravolatz","sequence":"first","affiliation":[{"name":"Ascension\u2013St John Hospital, Grosse Pointe Woods, and Wayne State University School of Medicine , East Lansing"},{"name":"Central Michigan University College of Medicine, Grosse Pointe Woods , East Lansing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E","family":"Stein","sequence":"additional","affiliation":[{"name":"Michigan State University School of Medicine , East Lansing"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,20]]},"reference":[{"key":"2024111411412019800_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02068-18","article-title":"In vitro activity of plazomicin against gram-negative and gram-positive bacterial pathogens isolated from patients in Canadian hospitals from 2013 to 2017 as part of the CANWARD Surveillance Study","volume":"63","author":"Walkty","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00313-18","article-title":"In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant enterobacteriaceae and isolates carrying carbapenemase genes","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0003","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drup.2010.08.003","article-title":"Aminoglycoside modifying enzymes","volume":"13","author":"Ramirez","year":"2010","journal-title":"Drug Resist Updat"},{"key":"2024111411412019800_CIT0004","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1021\/acsinfecdis.8b00001","article-title":"Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes","volume":"4","author":"Cox","year":"2018","journal-title":"ACS Infect Dis"},{"key":"2024111411412019800_CIT0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1086\/518605","article-title":"16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides","volume":"45","author":"Doi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024111411412019800_CIT0006","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1128\/AAC.44.12.3249-3256.2000","article-title":"Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance","volume":"44","author":"Kotra","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0007","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1021\/acsinfecdis.8b00052","article-title":"Effects of the 1- N-(4-amino-2 S-hydroxybutyryl) and 6\u2019- N-(2-hydroxyethyl) substituents on ribosomal selectivity, cochleotoxicity, and antibacterial activity in the sisomicin class of aminoglycoside antibiotics","volume":"4","author":"Sonousi","year":"2018","journal-title":"ACS Infect Dis"},{"key":"2024111411412019800_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0009","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/jac\/dku025","article-title":"Ceftazidime\/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)","volume":"69","author":"Flamm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024111411412019800_CIT0010","first-page":"3346","article-title":"Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms","volume":"73","author":"Castanheira","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024111411412019800_CIT0011","doi-asserted-by":"crossref","first-page":"e00236-18","DOI":"10.1128\/AAC.00236-18","article-title":"Evaluation of bactericidal activity of plazomicin and comparators against multidrug-resistant Enterobacteriaceae","volume":"62","author":"Thwaites","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0012","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/jac\/dkx261","article-title":"In vitro activity of plazomicin against \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE)","volume":"72","author":"Zhang","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024111411412019800_CIT0013","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/jac\/dkx239","article-title":"Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates","volume":"72","author":"Denervaud-Tendon","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024111411412019800_CIT0014","doi-asserted-by":"crossref","first-page":"ofz123","DOI":"10.1093\/ofid\/ofz123","article-title":"Plazomicin is active against metallo-\u03b2-lactamase-producing Enterobacteriaceae","volume":"6","author":"Serio","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024111411412019800_CIT0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01904-17","article-title":"In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0017","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.02744-13","article-title":"In vitro activity of plazomicin against 5015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012","volume":"58","author":"Walkty","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0018","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.diagmicrobio.2018.07.006","article-title":"Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae","volume":"92","author":"Thwaites","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024111411412019800_CIT0019","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1128\/AAC.00873-15","article-title":"Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?","volume":"59","author":"Garc\u00eda-Salguero","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0020","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1128\/AAC.00624-11","article-title":"Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects","volume":"55","author":"Cass","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02329-18","article-title":"Population pharmacokinetic analyses for plazomicin using pooled data from phase 1, 2, and 3 clinical studies","volume":"63","author":"Trang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0022","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/13543784.2015.1095180","article-title":"Plazomicin: an investigational therapy for the treatment of urinary tract infections","volume":"24","author":"Karaiskos","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"2024111411412019800_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01128-18","article-title":"A phase I study to assess the pharmacokinetics of intravenous plazomicin in adult subjects with varying degrees of renal function","volume":"62","author":"Komirenko","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0024","volume-title":"Ze","author":"Achaeogen","year":"2018"},{"key":"2024111411412019800_CIT0025","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.35.9.1875","article-title":"Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactams and two beta-lactamase inhibitors, cilastatin and heparin","volume":"35","author":"Walterspiel","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0026","first-page":"357","article-title":"In vivo inactivation of tobramycin by piperacillin","volume":"25","author":"Uber","year":"1991","journal-title":"DICP Ann Pharmacother"},{"key":"2024111411412019800_CIT0027","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2146\/ajhp170839","article-title":"Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration","volume":"75","author":"Asempa","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"2024111411412019800_CIT0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01989-17","article-title":"A multicenter, randomized, double blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis","volume":"62","author":"Connolly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0029","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"2024111411412019800_CIT0030","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"2024111411412019800_CIT0031","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1128\/AAC.00869-16","article-title":"Association between the presence of aminoglycoside-modifying enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase- and extended-spectrum-\u03b2-lactamase-producing enterobacter species","volume":"60","author":"Haidar","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412019800_CIT0032","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/jac\/dku517","article-title":"Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists","volume":"70","author":"Gilchrist","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024111411412019800_CIT0033","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.cmi.2018.07.020","article-title":"Developing a new antibiotic for extensively drug-resistant pathogens: the case of plazomicin","volume":"24","author":"Theuretzbacher","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024111411412019800_CIT0034","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijantimicag.2008.09.001","article-title":"Do we still need the aminoglycosides?","volume":"33","author":"Durante-Mangoni","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2024111411412019800_CIT0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkn469","article-title":"Aminoglycoside drugs in clinical practice: an evidence-based approach","volume":"63","author":"Leibovici","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2024111411412019800_CIT0036","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0025-6196(11)65134-3","article-title":"The aminoglycosides","volume":"74","author":"Edson","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"2024111411412019800_CIT0037","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024111411412019800_CIT0038","first-page":"79","article-title":"Ceftazidime\/avibactam (Avycaz)\u2014a new intravenous antibiotic","volume":"57","author":"Medical Letter","year":"2015","journal-title":"Med Lett Drugs Ther"},{"key":"2024111411412019800_CIT0039","first-page":"180","article-title":"Plazomicin (Zemdri)\u2014a new aminoglycoside antibiotic","volume":"60","author":"Medical Letter","year":"2018","journal-title":"Med Lett Drugs Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz640\/29183353\/ciz640.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/4\/704\/32312753\/ciz640.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/4\/704\/32312753\/ciz640.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T07:32:26Z","timestamp":1731569546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/4\/704\/5536695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,20]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,7,20]]},"published-print":{"date-parts":[[2020,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz640","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,15]]},"published":{"date-parts":[[2019,7,20]]}}}